Methods	Allocation: random, no further details. Blindness: double, no further details. Duration: 24 weeks. Design: parallel. Location: multicentre.
Participants	Diagnosis: (DSM-IV) schizophrenia or schizoaffective disorder, dominant depressive symptoms, MADRS ≥16. N=394. Age: 18-60 years. Gender: not reported. History: duration of illness not reported, age at onset not reported. Setting: in- and outpatient.
Interventions	Olanzapine: fixed dose: 10, 15 or 20 mg/day. N=202. Ziprasidone: fixed dose: 80, 120 or 160 mg/day. N=192.
Outcomes	Leaving the study early: any reason, adverse events, inefficacy. Global State: CGI. Mental State: PANSS total score, depression MADRS, Calgary depression scale for schizophrenia. General Functioning: GAF Adverse effects: open interviews, EPS (use of antiparkinson medication, AIMS, BAS, SAS), cardiac effects (ECG), weight gain, laboratory (prolactin, glucose, lipids) Unable to use- PANSS (no data).
Notes
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random, no further details.
Allocation concealment (selection bias)	Unclear risk	No further details.
Blinding (performance bias and detection bias) Subjective outcomes	Unclear risk	Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding
Blinding (performance bias and detection bias) Objective outcomes	Low risk	Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	The overall attrition was very high (62. 7%). The last observation carried forward method was used for people leaving the study early
Selective reporting (reporting bias)	High risk	Secondary outcomes were not fully reported.
Other bias	High risk	The study was sponsored by the manufacturer of olanzapine.